The University of Queensland (UQ) in Australia has progressed its Covid-19 vaccine candidate into preclinical testing stage.
Conducted in partnership with Dutch firm Viroclinics Xplore, the preclinical studies will assess the candidate’s effectiveness in triggering protection against the novel coronavirus.
Data from these studies should support the human clinical trials planned for later this year. Vaccine programme co-leader Dr Keith Chappell said: “These protection studies must be done in specialist biosecurity facilities as they use the live virus, and our long-standing partnership with Viroclinics Xplore gives us the confidence that this can be achieved as quickly as possible. “This work will establish a critical package of data